Dublin, Feb. 07, 2019 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2010 to 2018" report has been added to ResearchAndMarkets.com's offering. The Global Gene Therapy Partnering Terms and Agreements 2010-2018 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter gene Therapy Partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Highlights
- Trends in gene therapy partnering deals
- Disclosed headlines, upfronts, milestones and royalties by stage of development
- Gene Therapy Partnering contract documents
- Top gene therapy deals by value
Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Gene therapy dealmaking 2.1. Introduction 2.2. Gene therapy partnering over the years 2.3. Most active Gene therapy dealmakers 2.4. Gene therapy partnering by deal type 2.5. Gene therapy partnering by therapy area 2.6. Deal terms for Gene therapy partnering 2.6.1 Gene therapy partnering headline values 2.6.2 Gene therapy deal upfront payments 2.6.3 Gene therapy deal milestone payments 2.6.4 Gene therapy royalty rates Chapter 3 - Leading Gene therapy deals 3.1. Introduction 3.2. Top Gene therapy deals by value Chapter 4 - Most active Gene therapy dealmakers 4.1. Introduction 4.2. Most active Gene therapy dealmakers 4.3. Most active Gene therapy partnering company profiles Chapter 5 - Gene therapy contracts dealmaking directory 5.1. Introduction 5.2. Gene therapy contracts dealmaking directory Chapter 6 - Gene therapy dealmaking by technology type Chapter 7 - Partnering resource center 7.1. Online partnering 8.2. Partnering events 8.3. Further reading on dealmaking Appendices Appendix 1 - Gene therapy deals by company A-Z Appendix 2 - Gene therapy deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Gene therapy deals by deal type Asset purchase Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Evaluation Grant Joint venture Licensing Manufacturing Marketing Option Research Spin out Sub-license Supply Technology transfer Appendix 4 - Gene therapy deals by therapy area Cardiovascular Central Nervous System Genetic disorders Hematology Immunology Infectives Metabolic Musculoskeletal Obstetrics Oncology Ophthalmics Orphan disease Pediatrics Respiratory Appendix 5 - Deal type definitions For more information about this report visit https://www.researchandmarkets.com/research/h..._gene?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics
